VAS203

VAS203 is the first drug which targets Both blood vessels and tissue of the brain and represents a completely novel pharmacological approach.

Clinical Development

Clinical Development

The NOSTRA (NOSynthase Inhibition in TRAumatic brain injury) III trial examines VAS203 in patients who have sustained an acute brain injury. NOSTRA III is a European placebo-controlled, randomised, double-blind, multi-centre study entitled “Efficacy of VAS203 in patients with moderate and severe traumatic brain injury”. read on

Corporate Profile

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebrovascular diseases. We develop novel therapeutics for acute inflammatory central nervous system conditions by targeting nitric oxide signalling pathways. read on

Latest News

Latest News

Visit our news section for current news, press releases and additional information about the biopharmaceutical company vasopharm, its events, challenges and achievements. read on